Objective To investigate the clinical efficacy and cardiac function of nohintal(sacubactril valsartan sodium)combined with levosimendan in patients with valvular heart failure.Methods 150 patients with valvular heart failure admitted to our hospital from October 2019 to October 2022 were selected as research objects,and were divided into observation group and control group by random number table method,with 75 cases in each group.The control group was treated with levosimendan,and the observation group was treated with nocinol combined with levosimendan.After 3 courses of treatment,the clinical ef-ficacy,cardiac function,vascular endothelial function,myocardial injury markers and therapeutic safety of the two groups were evaluated.Results 1 case of voluntary withdrawal in the observation group,2 cases of adjustment of treatment plan,2 cases of voluntary withdrawal in the control group,and 1 case of missing observation index results were excluded from this study.The to-tal effective rate of observation group was 91.67%(66/72),which was higher than that of control group 77.78%(56/72)(P<0.05).After treatment,left ventricular ejection fraction(LVEF)and cardiac output(CO)in observation group were higher than those in control group,but left ventricular end-diastolic diameter(LVEDD)and left ventricular end-diastolic volume(LVEDV)in ob-servation group were lower than those in control group.After treatment,the levels of angioendothelin-1(ET-1)and angiotensin-II(Ang-II)in observation group were lower than those in control group,and the levels of nitric oxide(NO)were higher than those in control group.After treatment,the levels of cardiac fatty acid-binding protein(H-FABP),myoglobin(MYO)and extra-cellular matrix metalloproteinase-inducing factor(EMMPRIN)in observation group were lower than those in control group.The incidence of adverse reactions in the two groups was 11.11%(8/72)and 8.33%(6/72),respectively,and there was no significant difference between the two groups.Conclusion Nohintal combined with levosimendan has significant clinical efficacy in pa-tients with valvular heart failure,which can improve the cardiac function and vascular endothelial function,reduce the level of myocardial cell injury markers,and has good therapeutic safety.
万方数据
